Due to our finding that DbpA was more often present in ccRCC than YB-1 and that the pro-oncogenic effect of DbpA – alone or in concert with myr-Akt1 was stronger than the effect of YB-1 and that DbpA was able to overcome the anti-oncogenic interference of YB-1 and myr-Akt1, we conclude that DbpA is a powerful oncogene. The gene discussed is YBX3; the disease is nonpapillary renal cell carcinoma.